Skip to main content
Results of the ASCEND-7 phase II study evaluating ALK inhibitor (ALKi) ceritinib in patients (pts) with ALK plus non-small cell lung cancer (NSCLC) metastatic to the brain Chow, L. Q., Barlesi, F., Bertino, E. M., van den Bent, M. J., Wakelee, H., Wen, P. Y., Chiu, C., Orlov, S., Majem, M., Chiari, R., McKeage, M., Yu, C., Hurtado, F. K., Arratia, P., Song, Y., Branle, F., Shi, M., Kim, D. OXFORD UNIV PRESS. 2019: 602–3

View details for Web of Science ID 000491295504141